Wang B, et al. - Given that HBeAg seroconversion marks an important spontaneous change and treatment end-point for HBeAg-positive patients and is a pre-requisite for HBsAg loss or functional cure, researcher investigated the predictors of seroconversion using serum quantitative HBsAg and HBcrAg, in HBeAg-positive patients treated with nucleos(t)ide analogues (NA) in this retrospective analysis. They noted that a combination of HBsAg and HBcrAg had the greatest predictive value for HBeAg seroconversion. At 6 months, HBsAg of 3.9 log₁₀ IU/mL and HBcrAg of 5.7 log₁₀ U/mL had a sensitivity of 71.4%, specificity of 79.5%, positive predictive value (PPV) of 65.2% and negative predictive value (NPV) of 83.8%, with AUROC of 0.769, and at 12 months, HBsAg 3.8 log₁₀ IU/mL and HBcrAg 5.5 log₁₀ U/mL had a sensitivity of 73.7%, specificity of 79.5%, PPV of 63.6% and NPV of 86.1%, with AUROC 0.807.